Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy.

Minnock P, Ringnér A, Bresnihan B, Veale D, FitzGerald O, McKee G.

Musculoskeletal Care. 2017 Mar;15(1):23-35. doi: 10.1002/msc.1136. Epub 2016 Feb 12.

PMID:
26871999
2.

Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.

Minnock P, Veale DJ, Bresnihan B, FitzGerald O, McKee G.

Clin Rheumatol. 2015 Nov;34(11):1857-65. doi: 10.1007/s10067-015-3088-6. Epub 2015 Oct 9.

3.

How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study.

Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale DJ.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1597-603. doi: 10.1002/acr.22387.

4.

Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.

Walsh CE, Ryan EJ, O'Farrelly C, Golden-Mason L, FitzGerald O, Veale DJ, Bresnihan B, Fearon U.

PLoS One. 2011;6(11):e27182. doi: 10.1371/journal.pone.0027182. Epub 2011 Nov 15.

5.

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGerald O, Poole AR, Bresnihan B, Veale DJ, Fearon U.

Arthritis Rheum. 2012 Apr;64(4):1035-45. doi: 10.1002/art.33455. Epub 2011 Nov 10.

6.

The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.

Adams R, Craig BM, Walsh CD, Veale DJ, Bresnihan B, FitzGerald O, Barry M.

Value Health. 2011 Sep-Oct;14(6):921-7. doi: 10.1016/j.jval.2011.03.002. Epub 2011 Jul 8.

7.

Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.

Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, Fearon U, Bresnihan B, Tak PP, Gibney RG, Veale DJ, FitzGerald O.

Arthritis Res Ther. 2011 Jan 27;13(1):R7. doi: 10.1186/ar3228.

8.

Pulmonary fibrosis in systemic sclerosis: association with myocardial fibrosis.

Nicholson PJ, Hegarty C, Jackson M, Keane D, Fitzgerald O, Bresnihan B, Veale D, Dodd JD.

J Thorac Imaging. 2012 Jan;27(1):44-50. doi: 10.1097/RTI.0b013e3181fbf8c1.

PMID:
21107283
9.

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.

van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, van der Leij C, Maas M, Kraan MC, Tak PP.

Ann Rheum Dis. 2010 Nov;69(11):2013-6. doi: 10.1136/ard.2010.131235. Epub 2010 Aug 6. Erratum in: Ann Rheum Dis. 2013 Apr;72(4):630. van de Leij, Christiaan [corrected to van der Leij, Christiaan].

PMID:
20693270
10.

Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis.

Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B.

Clin Exp Rheumatol. 2010 May-Jun;28(3):401-4. Epub 2010 Jun 23.

PMID:
20525443
11.

Remission in psoriatic arthritis: is it possible and how can it be predicted?

Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021. Epub 2010 May 18.

12.

Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.

Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M.

Pharmacoeconomics. 2010;28(6):477-87. doi: 10.2165/11533010-000000000-00000.

PMID:
20465316
13.

Synovial tissue hypoxia and inflammation in vivo.

Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, Buggy D, Taylor CT, O'Sullivan J, Fearon U, Veale DJ.

Ann Rheum Dis. 2010 Jul;69(7):1389-95. doi: 10.1136/ard.2009.119776. Epub 2010 May 3.

14.

Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model.

Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, Mullan R, FitzGerald O, Bresnihan B, Pitzalis C, Veale DJ, Fearon U.

J Immunol. 2010 Jun 1;184(11):6427-37. doi: 10.4049/jimmunol.0902941. Epub 2010 Apr 30.

15.

A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.

Mullan RH, McCormick J, Connolly M, Bresnihan B, Veale DJ, Fearon U.

Am J Pathol. 2010 Apr;176(4):1999-2008. doi: 10.2353/ajpath.2010.090014. Epub 2010 Mar 19.

16.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
17.

Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.

Ng CT, Radovits BJ, Kievit W, Fransen J, van Riel PL, FitzGerald O, Veale DJ, Bresnihan B.

Ann Rheum Dis. 2010 Jan;69(1):313-4. doi: 10.1136/ard.2009.107748. No abstract available.

PMID:
20007623
18.

Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.

Rooney T, Edwards CK 3rd, Gogarty M, Greenan L, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B.

Rheumatol Int. 2010 Nov;30(12):1571-80. doi: 10.1007/s00296-009-1191-1. Epub 2009 Oct 22.

PMID:
19847430
19.

Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.

Minnock P, Kirwan J, Bresnihan B.

Rheumatology (Oxford). 2009 Dec;48(12):1533-6. doi: 10.1093/rheumatology/kep287. Epub 2009 Sep 22.

PMID:
19773406
20.

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.

Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW.

Ann Rheum Dis. 2010 Mar;69(3):483-9. doi: 10.1136/ard.2009.113100. Epub 2009 Sep 17. Review.

PMID:
19762361
21.

Assessing quality of sleep in patients with rheumatoid arthritis.

Wells GA, Li T, Kirwan JR, Peterson J, Aletaha D, Boers M, Bresnihan B, Dougados M, Idzerda L, Nicklin J, Suarez-Almazor M, Welch V, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2077-86. doi: 10.3899/jrheum.090362. Review.

PMID:
19738217
22.

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.

Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP.

J Rheumatol. 2009 Aug;36(8):1800-2. doi: 10.3899/jrheum.090348.

PMID:
19671815
23.

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database.

Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland ML, Peets T, Immonen K, Maillefert JF, Drosos AA, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y.

Ann Rheum Dis. 2009 Nov;68(11):1666-72. doi: 10.1136/ard.2009.109983. Epub 2009 Jul 30.

24.

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U.

Arthritis Res Ther. 2009;11(4):R113. doi: 10.1186/ar2772. Epub 2009 Jul 23.

25.

Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade.

Rooney T, Roux-Lombard P, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B.

Ann Rheum Dis. 2010 Apr;69(4):706-14. doi: 10.1136/ard.2009.108324. Epub 2009 May 20.

PMID:
19460761
26.

Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, Codd MB, Dodd J, Veale D, Fitzgerald O, Bresnihan B.

Ann Rheum Dis. 2010 Jan;69(1):181-5. doi: 10.1136/ard.2008.101857.

PMID:
19176545
27.

Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.

Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Géher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T; QUEST-RA Group.

Arthritis Res Ther. 2009;11(1):R7. doi: 10.1186/ar2591. Epub 2009 Jan 14.

28.

An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions.

Doran JP, Alraqi S, Callanan I, FitzGerald O, Bresnihan B, Veale DJ.

Ir J Med Sci. 2009 Dec;178(4):497-501. doi: 10.1007/s11845-008-0274-4.

PMID:
19129975
29.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. No abstract available. Erratum in: Ann Rheum Dis. 2009 Mar;68(3):452. Kavanaugh, A [added].

PMID:
19022808
30.

Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis.

Murphy E, Roux-Lombard P, Rooney T, Fitzgerald O, Dayer JM, Bresnihan B.

Clin Rheumatol. 2009 Mar;28(3):285-91. doi: 10.1007/s10067-008-1037-3. Epub 2008 Nov 26.

PMID:
19050823
31.

Fatigue is related to poor pain outcomes in women with established rheumatoid arthritis.

Minnock P, Bresnihan B.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):707-8. No abstract available.

PMID:
18799112
32.

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.

Walsh CA, Fearon U, FitzGerald O, Veale DJ, Bresnihan B.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):656-8.

PMID:
18799100
33.

Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.

Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, Veys EM, De Keyser F, Bresnihan B, Luyten FP, Verdonk PC, Tak PP, Boots AH, Baeten D.

Ann Rheum Dis. 2009 Jun;68(6):1044-50. doi: 10.1136/ard.2007.085837. Epub 2008 Jul 16.

PMID:
18633128
34.

Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.

Keane J, Bresnihan B.

Curr Opin Rheumatol. 2008 Jul;20(4):443-9. doi: 10.1097/BOR.0b013e3283025ec2. Review.

PMID:
18525359
35.

Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry.

Murphy E, Bresnihan B, FitzGerald O.

Clin Rheumatol. 2008 Jun;27(6):763-6. doi: 10.1007/s10067-007-0833-5. Epub 2008 Feb 21.

PMID:
18288445
36.

Consistency in assessing the Disease Activity Score-28 in routine clinical practice.

Walsh CA, Mullan RH, Minnock PB, Slattery C, FitzGerald O, Bresnihan B.

Ann Rheum Dis. 2008 Jan;67(1):135-6. No abstract available.

PMID:
18077544
37.

Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy.

Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, Fearon U, Veale DJ.

Arthritis Rheum. 2007 Sep;56(9):2919-28.

38.

Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis.

Rooney T, Bresnihan B, Andersson U, Gogarty M, Kraan M, Schumacher HR, Ulfgren AK, Veale DJ, Youssef PP, Tak PP.

Ann Rheum Dis. 2007 Dec;66(12):1656-60. Epub 2007 Jun 29.

39.

Differential expression of syndecans and glypicans in chronically inflamed synovium.

Patterson AM, Cartwright A, David G, Fitzgerald O, Bresnihan B, Ashton BA, Middleton J.

Ann Rheum Dis. 2008 May;67(5):592-601. Epub 2007 Jun 1.

40.

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ, Bresnihan B, FitzGerald O.

Rheumatology (Oxford). 2007 Jul;46(7):1148-52. Epub 2007 May 3.

PMID:
17478471
41.

Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis.

Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, Hazes M, Richards P, Saag K, Suarez-Almazor M, Wells G, Hewlett S.

J Rheumatol. 2007 May;34(5):1174-7.

PMID:
17477482
42.

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.

Sokka T, Kautiainen H, Toloza S, Mäkinen H, Verstappen SM, Lund Hetland M, Naranjo A, Baecklund E, Herborn G, Rau R, Cazzato M, Gossec L, Skakic V, Gogus F, Sierakowski S, Bresnihan B, Taylor P, McClinton C, Pincus T; QUEST-RA Group.

Ann Rheum Dis. 2007 Nov;66(11):1491-6. Epub 2007 Apr 5.

43.

Assessing single joints in arthritis clinical trials.

Giles JT, Mease P, Boers M, Bresnihan B, Conaghan PG, Heald A, Maksymowych WP, Maillefert JF, Simon L, Tsuji W, Wakefield R, Woodworth T, Schumacher HR, Bingham CO 3rd.

J Rheumatol. 2007 Mar;34(3):641-7.

PMID:
17343312
44.

Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers.

Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, Fitzgerald O, Kirkham BW, McInnes IB, Smith M, Ulfgren AK, Veale DJ, Tak PP.

J Rheumatol. 2007 Mar;34(3):620-2.

PMID:
17343309
45.

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G.

J Rheumatol. 2007 Mar;34(3):607-15.

PMID:
17343307
46.

A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue.

Ralph JA, Zocco D, Bresnihan B, Fitzgerald O, McEvoy AN, Murphy EP.

Am J Pathol. 2007 Mar;170(3):1121-33.

47.

Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.

Markham T, Mathews C, Rogers S, Mullan R, Bresnihan B, Fitzgerald O, Veale DJ, Fearon U.

Br J Dermatol. 2006 Dec;155(6):1191-6.

PMID:
17107388
48.

Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.

Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ.

Arthritis Rheum. 2006 Oct;54(10):3152-62.

49.

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP.

Arthritis Rheum. 2006 Aug;54(8):2387-92.

50.

Synovial biomarkers in the spondylarthropathies.

Bresnihan B.

Curr Opin Rheumatol. 2006 Jul;18(4):359-63. Review.

PMID:
16763455

Supplemental Content

Loading ...
Support Center